Access Pharmaceuticals rebrands, aims for siRNA

Dallas-based Access Pharmaceuticals is reporting that it has made progress with its Cobalamin-targeted drug-delivery program for siRNA therapies. Indeed, it has rebranded its targeted-drug delivery technology as CobaCyte and submitted additional patent applications. We reported back in July that Access Pharmaceuticals and an unnamed partner are testing out a proprietary nanopolymer oral drug--a Trojan Horse that hitches a ride on the body's natural vitamin B12 uptake mechanism. They were testing the product out for oral delivery, rather than injections, of insulin and human growth hormone. It sounds as though delivery of gene-silencing therapeutics is up their sleeve as well. Access release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.